New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim data on
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023Phase 2b clinical trial reduced in size and expected to reach interim. | March 28, 2023
COPENHAGEN, Denmark, March 14, 2023), taking place from April 14th to April 19th in Orlando, Florida. Pér Norlen, CEO at Evaxion, said: "Our unique AI platform PIONEER has allowed the development of
Investegate announcements from Evaxion Biotech, Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)